Megestrol acetate therapy for advanced breast cancer
| Autor: | Ernest J. Gregory, Charles H. Mims, Stephen C. Cohen, Donald W. Oines |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Bone Neoplasms Breast Neoplasms Gastroenterology Stable Disease Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Chemotherapy business.industry Megestrol Acetate Body Weight Cancer Megestrol medicine.disease Metastatic breast cancer Surgery Menopause Methotrexate Receptors Estrogen Oncology Megestrol acetate Toxicity Drug Evaluation Female Fluorouracil medicine.symptom Receptors Progesterone business Weight gain medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 3:155-160 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1985.3.2.155 |
| Popis: | One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily. Complete responses (CR) or partial responses (PR) were seen in 29 patients (23%). CR, PR, or stable disease (S) was seen in 80 patients (65%). The median duration of response was 22 months for CR and PR and ten months for S. A significantly higher response rate (CR + PR) was seen in estrogen-receptor-positive (ER-positive) patients (26%) and in patients who had not received prior therapy (39%). A significant relationship to response could not be established for menopausal status, progesterone-receptor (PrR) status, dominant site of disease, or prior administration of chemotherapy. Median survival was 66+ months for responders, 35 months for patients with stable disease, and 9 months for nonresponders. These differences are all statistically significant (P less than .001). Toxicity was minimal, and side effects consisted primarily of weight gain, which was seen in 18 patients (14.5%). Megestrol acetate can provide effective palliation in patients with advanced breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|